Wound Dressing Binder
report_problem Problem Statement
Advanced wound dressings use synthetic adhesives and crosslinked hydrocolloid matrices that can cause skin stripping injuries on removal, trigger contact dermatitis, and leave synthetic residues in the wound bed. Current bio-based alternatives (alginate, collagen sponges) have limited wet strength and require secondary fixation. A bio-based wound binder using food-grade crosslinking agents could create moist-healing dressings with gentle, moisture-responsive adhesion and full bioabsorbability.
trending_up Market Size
$3.4B
gavel Regulatory Drivers
FDA 510(k) wound dressing classification (21 CFR 878.4018); EU MDR 2017/745 Class IIa medical device; ISO 10993-1 biological evaluation framework; ISO 10993-10 (irritation and sensitization); USP <381> elastomeric closures compatibility; CMS Medicare Part B wound care coverage requirements; NHS Wound Care Formulary specifications
corporate_fare Enterprise Interest
No enterprise interest recorded yet. Companies can indicate their volume and urgency to help guide research priorities.
flag Success Criteria
Achieve absorption capacity ≥15 g/100cm², wet tensile strength ≥0.5 N/mm, peel adhesion 0.1-0.5 N/25mm (gentle removal range), cell viability >90% per ISO 10993-5, and no sensitization response on EpiDerm model
precision_manufacturing Equipment Needed
Film casting equipment, Suter apparatus or modified setup for MVTR, universal testing machine with wet grips, 90° peel test fixture, porcine skin (from abattoir or tissue supplier), cell culture facility, EpiDerm tissue kit, fluid absorption test apparatus (EN 13726-1), lyophilizer, SEM for microstructure characterization, sodium alginate, gelatin, commercial dressings for comparison
menu_book Existing References
Reference list will be published with protocols.
Protected Research Content
This section contains detailed protocols, proposed mechanisms, experiment designs, and safety information.
Already have an account? Login